Predicting the response to targeted therapy in metastatic colorectal cancer

Arun Azad, Niall C. Tebbutt

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Colorectal cancer is the second most common cause of cancer-related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.

Original languageEnglish
Pages (from-to)208-217
Number of pages10
JournalAsia-Pacific Journal of Clinical Oncology
Volume4
Issue number4
DOIs
Publication statusPublished - 2008
Externally publishedYes

Keywords

  • Angiogenesis inhibitor
  • Colorectal cancer
  • Drug response biomarkers
  • Epidermal growth factor receptor
  • K-ras oncogene

Cite this

@article{583353bd5eaa4932851ed89906390670,
title = "Predicting the response to targeted therapy in metastatic colorectal cancer",
abstract = "Colorectal cancer is the second most common cause of cancer-related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.",
keywords = "Angiogenesis inhibitor, Colorectal cancer, Drug response biomarkers, Epidermal growth factor receptor, K-ras oncogene",
author = "Arun Azad and Tebbutt, {Niall C.}",
year = "2008",
doi = "10.1111/j.1743-7563.2008.00215.x",
language = "English",
volume = "4",
pages = "208--217",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "4",

}

Predicting the response to targeted therapy in metastatic colorectal cancer. / Azad, Arun; Tebbutt, Niall C.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 4, No. 4, 2008, p. 208-217.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Predicting the response to targeted therapy in metastatic colorectal cancer

AU - Azad, Arun

AU - Tebbutt, Niall C.

PY - 2008

Y1 - 2008

N2 - Colorectal cancer is the second most common cause of cancer-related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.

AB - Colorectal cancer is the second most common cause of cancer-related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.

KW - Angiogenesis inhibitor

KW - Colorectal cancer

KW - Drug response biomarkers

KW - Epidermal growth factor receptor

KW - K-ras oncogene

UR - http://www.scopus.com/inward/record.url?scp=57849138484&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2008.00215.x

DO - 10.1111/j.1743-7563.2008.00215.x

M3 - Review Article

VL - 4

SP - 208

EP - 217

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 4

ER -